Axe Compute Inc. Q1 FY2023 earnings call

• Raymond Vennare discussed the company's assets including PeDAL, CORE, and a biobank of over 150,000 tumor samples. • Partnerships with Cancer Research Horizon (CRH) to identify suitable patient populations for drug development, and with Cvergenx to develop genomic-based precision radiation therapy. • Collaborations with Flugen Inc. on a next-gen vaccine and Integra Therapeutics using proprietary chromatography for drug development. • Additions to Scientific Advisory Board and Board of Directors, including Christoph Reinhardt, Veena Rao, etc.

No detailed product segment financial performance with revenue contribution % provided. Overall, cash and cash equivalents were $18.6 million as of March 31, 2023, down from $22.1 million on Dec 31, 2022. Q1 2023 revenue was $0.2 million vs $0.3 million in Q1 2022. Gross margin was 50% in Q1 2023 vs 65% in Q1 2022.

• Revenue potential from fee-for-service contracts, with expectation of revenue growth in the fiscal year. • Skyline's agreement in Canada with 20 hospitals will bring in revenue in the next six months or less. • Anticipation of revenue from PeDAL and other partnerships to accelerate growth and move towards breakeven.

• Mention of a singular lawsuit involving former employees, but Bob Myers stated the company is committed to resolving it with minimal impact to investors and the company.

Q: What is the timeline for breakeven and how many molecules have been looked at under the Cancer Research Horizon partnership?

A: Pamela Bush said they're working on the first program with Cancer Research UK, can't disclose number of molecules, expecting results before end of Q3.

Q: Can you confirm there's a compound being worked on with milestone payments?

A: Pamela Bush confirmed there is a compound being worked on, with results expected before end of Q3.

Q: Concerns about lawsuits from former employees?

A: Bob Myers stated it's a singular lawsuit with minimal impact and the company is committed to resolving it.

Q: Color on the relationship with Flugen?

A: Raymond Vennare and Pamela Bush said it's a fee-for-service project to advance biologics, details to be shared when project is complete.

Q: Revenue growth and breakeven in next 12 months?

A: Bob Myers said revenue potential is greater, Skyline's agreement will bolster revenue, and working on closing deals like CRH to accelerate growth towards breakeven.